KO Client Predicine Collaborates with Janssen to Develop PredicineCARE™ for Bladder Cancer

KO client Predicine, Inc., a leading molecular insights company committed to advancing precision medicine in oncology, recently announced a collaboration with Janssen Pharmaceutica NV, a Johnson & Johnson company, to develop PredicineCARE™ as a companion diagnostic assay in localized bladder cancer.

The collaboration represents progress in using comprehensive genomic profiling for the detection of select alterations in localized bladder cancer that may benefit from targeted therapy.

In the press release, Dr. Shidong Jia, Predicine’s Founder, Chairman, and CEO, said, “We are delighted to collaborate with Janssen to develop a cfDNA urine-based assay designed to identify patients with localized bladder cancer who may harbor select alterations and may benefit from targeted therapy.”

KO partner Brad Schoenfeld represented Predicine in this collaboration.

“Brad at KO Law Firm was critical to completing this significant collaboration with Janssen,” said Alexander Kuklin, PhD, VP BioPharma Partnerships at Predicine, Inc. “He provided a strong combination of smart legal counsel and significant life sciences industry expertise that was invaluable to securing this partnership and thereby providing better treatment for bladder cancer patients in the future.”

To learn more about the announcement, check out the press release.